Pichia pastoris engineering bacterium for producing new coronavirus recombinant antigen as well as preparation method and application of pichia pastoris engineering bacterium

By modifying the Pichia pastoris strain, the problem of uneven glycosylation was solved, achieving efficient and stable expression and uniform glycosylation of the SARS-CoV-2 RBD antigen, generating high levels of neutralizing antibodies, and improving the protective effect of the vaccine.

CN118909811APending Publication Date: 2024-11-08INST OF MICROBIOLOGY CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410316772.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-03-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In existing Pichia pastoris expression systems, the glycosylation modification of recombinant SARS-CoV-2 proteins is uneven, leading to unstable protein expression during vaccine production and affecting the industrialization process of vaccines.

Method used

By knocking out the α-1,6-mannose transferase gene in Pichia pastoris strain GS115 and restoring the histidine-deficient type, a glycosylated modified Pichia pastoris engineered strain was constructed. This recombinant Pichia pastoris engineered strain expressed the SARS-CoV-2 S protein RBD antigen. The gene was introduced using an Escherichia coli-Pichia pastoris shuttle expression vector to ensure efficient protein expression and uniformity of glycosylation modification.

Benefits of technology

It achieves efficient and stable expression and glycosylation uniformity of the SARS-CoV-2 RBD dimer antigen, which can induce high levels of neutralizing antibodies and has a broad-spectrum vaccine protective effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides a modified pichia pastoris strain and a preparation method thereof, a recombinant pichia pastoris engineering strain based on the modified pichia pastoris strain and used for expressing a novel coronavirus antigen, a preparation method and application of the recombinant pichia pastoris engineering strain, and a method for preparing a novel coronavirus recombinant protein vaccine. The modified pichia pastoris expression vector not only can express and secrete recombinant protein at a high level, but also can enable the expressed recombinant protein to retain core glycosylation modification, and glycoprotein secreted by the modified pichia pastoris expression vector has better uniformity; recombinant pichia pastoris engineering bacteria which are based on the pichia pastoris expression vector and express the novel coronavirus antigen can efficiently produce the high-quality RBD dimer antigen with uniform glycosylation, and the produced RBD dimer antigen can be used as an immunogen to induce generation of a high-level neutralizing antibody aiming at a novel coronavirus prototype strain and a variant strain of the novel coronavirus prototype strain.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This application claims priority to the Chinese patent application filed on May 8, 2023, with application number 202310513084.8 and invention name “Pichia pastoris engineered bacteria for producing recombinant coronavirus antigens, preparation methods and applications thereof”, the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present invention belongs to the field of bioengineering technology, and specifically relates to an engineered Pichia pastoris for producing a recombinant antigen of a novel coronavirus, a preparation method thereof, and an application thereof in the preparation of a novel coronavirus vaccine. Background Art

[0004] Novel coronavirus infection (also known as COVID-19) is an acute respiratory infectious disease caused by the novel coronavirus (also known as the new coronavirus, SARS-CoV-2). The new coronavirus belongs to the genus Beta-coronavirus of the Coronaviridae family and is a positive-strand RNA enveloped virus. The spike (S) protein on the surface of the new coronavirus envelope plays an important role in viral invasion. The S protein contains S1 and S2 subunits. The receptor binding domain (RBD) of the S1 subunit is responsible for binding to the viral receptor protein ACE2 (Angiotensin-converting enzyme 2), and the S2 subunit is responsible for mediating membrane fusion. Therefore, the S protein, especially the RBD, is an important target for designing a new coronavirus vaccine. The Institute of Microbiology, Chinese Academy of Sciences, developed a recombinant subunit protein vaccine ZF2001 based on the new coronavirus RBD dimer using a mammalian cell expression system. It showed good immunogenicity and protective effects in subsequent clinical trials and has been widely used and promoted at home and abroad.

[0005] In experimental research on recombinant proteins, compared with mammalian cell expression systems, the production of recombinant proteins using yeast cell expression systems has the characteristics of low cost and high productivity. Therefore, yeast cells have become one of the important eukaryotic expression hosts for industrial production of protein products.

[0006] Pichia pastoris is a typical yeast strain with the advantages of high expression, low culture cost, simple molecular manipulation, easy to obtain stable genetic strains, and large-scale production. It has been used in the production of vaccines such as hepatitis B vaccine. In the Pichia pastoris expression system, protein expression has two expression modes: intracellular expression and secretory expression. Among them, secretory expression has become the preferred expression mode of protein due to its simple protein acquisition process and low cost. Proteins will undergo post-translational modification during the secretion process, among which glycosylation modification is a very important aspect. Yeast cell secretory proteins often have uneven polymannan modification, especially proteins containing multiple N-glycosylation sites, which seriously hinders the industrialization process of yeast vaccines. Therefore, the development of Pichia pastoris engineered strains with improved glycosylation has become one of the breakthroughs in solving this problem and one of the current focuses in the field of protein expression.

[0007] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention and should not be regarded as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art. Summary of the invention

[0008] Purpose of the Invention

[0009] In view of the defects existing in the above-mentioned prior art, the object of the present invention is to provide a modified Pichia pastoris strain and a preparation method thereof, a recombinant Pichia pastoris engineered bacterium expressing a novel coronavirus antigen based on the modified Pichia pastoris strain and a preparation method and use thereof, as well as a method for preparing a recombinant protein vaccine for the novel coronavirus.

[0010] Solution

[0011] To achieve the purpose of the present invention, the present invention provides the following technical solutions:

[0012] In a first aspect, the present invention provides a modified Pichia pastoris strain (hereinafter also referred to as GSΔoch1pAO strain), wherein the modified Pichia pastoris strain is obtained by knocking out the α-1,6-mannosyltransferase gene and complementing the histidine deficiency on the basis of the Pichia pastoris GS115 strain.

[0013] The modified Pichia pastoris strain can be obtained by the following method:

[0014] The α-1,6-mannosyltransferase gene (ie, OCH1 gene) in the Pichia pastoris GS115 strain is knocked out by genetic engineering means well known to those skilled in the art, and then a histidinol dehydrogenase coding sequence is introduced therein to complement the histidine deficiency.

[0015] In a second aspect, the present invention provides a method for preparing the modified Pichia pastoris strain as described in the first aspect above, characterized in that the preparation method comprises the following steps:

[0016] (1) By genetic engineering, the α-1,6-mannosyltransferase gene in the Pichia pastoris GS115 strain was knocked out to obtain the GSΔoch1 strain;

[0017] (2) After linearizing the exogenous histidinol dehydrogenase expression plasmid, the plasmid was integrated into the GSΔoch1 strain to obtain the modified Pichia pastoris strain.

[0018] Preferably, the exogenous histidinol dehydrogenase expression plasmid is an expression plasmid comprising a histidinol dehydrogenase gene (HIS4) in a vector pAOαM, for example, a recombinant expression plasmid as shown in SEQ ID NO:10.

[0019] In a third aspect, the present invention provides a recombinant Pichia pastoris engineered bacterium, wherein the recombinant Pichia pastoris engineered bacterium is obtained by introducing the coding sequence of the SARS-CoV-2 S protein RBD antigen into the modified Pichia pastoris strain as described in the first aspect above.

[0020] In a preferred embodiment, the SARS-CoV-2 S protein RBD antigen is a homozygous or chimeric dimer of the S protein RBD region of the SARS-CoV-2 prototype strain and / or its variant strain; wherein the SARS-CoV-2 variant strain is selected from: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Omicron subtype BA.1, BA.1.1, BA.2, BA.2.12.1, BA.3, BA.4, BA.5, BQ.1.1, and XBB.

[0021] In a preferred specific embodiment, the novel coronavirus S protein RBD antigen is a dimer formed by amino acid fragments at positions 329-537 of the S protein RBD region of the SARS-CoV-2 prototype strain and / or its variants through a linker or directly connected in series, preferably a dimer formed by direct connection in series;

[0022] Further preferably, the novel coronavirus S protein RBD antigen is a dimer formed by directly connecting amino acid fragments at positions 329-537 of the S protein RBD region of the prototype strain and the prototype strain (ie, prototype-prototype), the prototype strain and the Beta variant (ie, prototype-Beta), the Beta variant and the Delta variant (ie, Beta-Delta), the Delta variant and the Omicron variant (including Delta-Omicron BA.1, Delta-OmicronBA.4, Delta and Omicron BA.5, Delta-Omicron XBB, Delta-Omicron BQ.1.1), or the Omicron variant and the Omicron variant (for example, Omicron XBB-Omicron BQ.1.1, Omicron XBB-Omicron BA.5);

[0023] More preferably, the novel coronavirus S protein RBD antigen is selected from:

[0024] (1) a dimer formed by directly connecting the amino acid fragments 329-537 of the S protein RBD region of the prototype strain and the Beta variant, whose amino acid sequence is shown in SEQ ID NO: 1, preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO: 2;

[0025] (2) a dimer formed by directly connecting the amino acid fragment 329-537 of the RBD region of the S protein of Delta and Omicron BA.1 in series, wherein the amino acid sequence is as shown in SEQ ID NO:3, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO:4;

[0026] (3) a dimer formed by directly connecting the amino acid fragment 329-537 of the RBD region of the S protein of Delta and Omicron BA.5 in series, wherein the amino acid sequence is as shown in SEQ ID NO: 11, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO: 12;

[0027] (4) a dimer formed by directly connecting the amino acid fragment 329-537 of the S protein RBD region of Delta and Omicron BQ.1.1 in series, wherein the amino acid sequence is as shown in SEQ ID NO: 13, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO: 14;

[0028] (5) a dimer formed by directly connecting the amino acid fragment 329-537 of the S protein RBD region of Delta and Omicron XBB in series, wherein the amino acid sequence is as shown in SEQ ID NO: 15, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO: 16;

[0029] (6) A dimer formed by directly connecting the amino acid fragment 329-537 of the S protein RBD region of Omicron XBB and Omicron BA.5 in series, wherein the amino acid sequence is shown in SEQ ID NO: 17, and preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO: 18.

[0030] In a fourth aspect, the present invention provides a method for preparing the recombinant Pichia pastoris engineered bacteria as described in the third aspect above, the preparation method comprising the following steps:

[0031] The coding sequence of the SARS-CoV-2 S protein RBD antigen is cloned into a Pichia pastoris expression vector to obtain a recombinant expression plasmid; after linearization, the obtained recombinant expression plasmid is transferred into the modified Pichia pastoris strain as described in claim 1 to obtain the recombinant Pichia pastoris engineered bacteria.

[0032] Preferably, the Pichia pastoris expression vector comprises the following elements: a promoter, an α-mating factor signal, a Kex2 protease recognition site, a multiple cloning site, a C-terminal His tag, and a terminator; optionally, the promoter is an AOX promoter; optionally, the terminator is an AOX terminator;

[0033] Further preferably, the Pichia pastoris expression vector is selected from: Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα, pPICZαA, pPICZαB, pPICZαC, pPIC9K, PichiaPink TM ; In a specific embodiment, the Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα is used as the Pichia pastoris expression vector, and the nucleic acid sequence of the pMPICZα is shown in SEQ ID NO:5.

[0034] Optionally, the linearized recombinant expression plasmid is transferred into the modified Pichia pastoris strain as claimed in claim 1 by electroporation;

[0035] In a preferred embodiment, the preparation method comprises:

[0036] 1) Cloning the coding sequence of the SARS-CoV-2 S protein RBD antigen into a Pichia pastoris expression vector, preferably an Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα, to obtain a recombinant expression plasmid;

[0037] 2) linearizing the recombinant expression plasmid obtained in step 1) by enzyme digestion;

[0038] 3) preparing competent cells of the modified Pichia pastoris strain as claimed in claim 1;

[0039] 4) The linearized recombinant expression plasmid obtained in step 2) is transferred into the competent cells obtained in step 3) by electroporation to obtain the recombinant Pichia pastoris engineered bacteria.

[0040] In the fifth aspect, the present invention provides the use of the recombinant Pichia pastoris engineered bacteria as described in the third aspect above in the preparation of a recombinant protein vaccine for the new coronavirus.

[0041] In the sixth aspect, the present invention provides a method for preparing a recombinant protein vaccine of the new coronavirus, the method comprising: fermenting and culturing the recombinant Pichia pastoris engineered bacteria as described in the third aspect above, collecting the supernatant, and isolating the expressed new coronavirus S protein RBD antigen therefrom.

[0042] Beneficial Effects

[0043] The inventors of the present invention constructed a glycosylation-modified Pichia pastoris strain by knocking out the α-1,6-mannosyltransferase gene and complementing the histidine deficiency, and provided a recombinant Pichia pastoris engineered bacterium expressing a new coronavirus antigen based on the Pichia pastoris expression vector.

[0044] The glycosylation-modified Pichia expression vector provided by the present invention can not only express and secrete recombinant proteins at a high level, but also enable the expressed recombinant proteins to retain the core glycosylation modification, and the secreted glycoproteins have good uniformity; further, the recombinant Pichia engineered bacteria expressing the new coronavirus antigen based on the Pichia expression vector provided by the present invention can produce new coronavirus RBD dimer antigens with more uniform glycosylation at a higher yield, and the produced new coronavirus RBD dimer antigens have high quality, can be used as a vaccine to induce the production of high levels of neutralizing antibodies against the prototype strain of the new coronavirus and a series of variants, and are expected to become a broad-spectrum vaccine for the prevention of the new coronavirus. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] One or more embodiments are exemplarily described by the pictures in the accompanying drawings, and these exemplary descriptions do not constitute limitations on the embodiments. The special word "exemplary" here means "used as an example, embodiment or illustrative". Any embodiment described as "exemplary" here is not necessarily interpreted as being superior or better than other embodiments.

[0046] Figure 1 The RBD dimer protein PP purified by nickel affinity column as described in Example 3 of the present invention is shown0 and PB 0 The absorbance curve of the eluate subjected to molecular sieve chromatography (to further purify the protein) and the SDS-PAGE identification results of the collected elution peaks; wherein the arrows on the absorbance curve indicate PP 0 and PB 0 elution peak.

[0047] Figure 2 The engineered strain GSΔoch1-PB described in Example 5 of the present invention is shown 0 -His growth curve and the expression of RBD dimer protein in its 72h fermentation broth detected by Western blot.

[0048] Figure 3 The engineered strain GSΔoch1pAO-PB described in Example 8 of the present invention is shown 0 -His growth curve and the expression of RBD dimer protein in its 72h fermentation broth detected by Western blot.

[0049] Figure 4 The RBD dimer protein PB purified by nickel affinity column as described in Example 9 of the present invention is shown 0 The absorbance curve of the eluate subjected to molecular sieve chromatography (to further purify the protein) and the SDS-PAGE identification results of the collected elution peaks.

[0050] Figure 5 A shows the construction design of six RBD dimer proteins described in Example 10 of the present invention; Figure 5 B shows the expression of RBD dimer proteins in the fermentation broth detected by Western blot after 72 hours of shake flask fermentation of the recombinant engineered strain containing six RBD dimer proteins described in Example 11 of the present invention.

[0051] Figure 6 The absorbance curve of the eluate of the RBD dimer protein PB purified by a nickel affinity column subjected to molecular sieve chromatography (to further purify the protein) as recorded in Example 12 of the present invention, and the SDS-PAGE identification results of the collected elution peaks are shown; wherein the arrow indicates the elution peak of the PB protein and the SDS-PAGE identification results of the elution peak.

[0052] Figure 7The absorbance curve of the eluate of the RBD dimer protein D-BA.1 purified by a nickel affinity column and subjected to molecular sieve chromatography (to further purify the protein) as recorded in Example 13 of the present invention, and the SDS-PAGE identification results of the collected elution peaks are shown; wherein the arrow indicates the elution peak of the D-BA.1 protein and the SDS-PAGE identification results of the elution peak.

[0053] Figure 8 The results of antibody level detection in the serum collected from mice after the second immunization with the immunogen and the serum collected after the third immunization as described in Example 14 of the present invention are shown.

[0054] Fig. 9 The results show the neutralization titer of the sera collected from mice after the third immunization with the immunogen recorded in Example 15 of the present invention against the pseudovirus of the prototype strain of the new coronavirus and a series of variant strains.

[0055] Fig.10 The SDS-PAGE identification results of the RBD dimer protein D-BA.5 purified by nickel affinity column as described in Example 16 of the present invention are shown.

[0056] Fig.11 The SDS-PAGE identification results of the RBD dimer protein D-BQ.1.1 purified by a nickel affinity column as described in Example 17 of the present invention are shown.

[0057] Fig.12 The SDS-PAGE identification results of the RBD dimer protein D-XBB purified by nickel affinity column described in Example 18 of the present invention are shown.

[0058] Fig.13 The SDS-PAGE identification results of the RBD dimer protein XBB-BA.5 purified by nickel affinity column as described in Example 19 of the present invention are shown.

[0059] Fig.14 The results of the detection of specific binding antibody levels in the serum collected from mice after the second immunization with the immunogen and the serum collected after the third immunization as described in Example 20 of the present invention are shown.

[0060] Fig.15 The results of neutralizing antibody titer test against the prototype strain of the new coronavirus and a series of pseudoviruses of variant strains in the serum collected from mice after the third immunization with the immunogen recorded in Example 21 of the present invention are shown.

[0061] Fig.16The results of neutralization titer test of sera collected from mice at the 2nd week (corresponding to "8w" in the figure) and the 16th week (corresponding to "22w" in the figure) after the third immunization with the immunogen recorded in Example 22 of the present invention against pseudoviruses of the prototype strain of the new coronavirus and a series of mutant strains are shown.

[0062] Fig.17 The results recorded in Example 23 of the present invention show the neutralization titer results of the pseudovirus of the prototype strain of the new coronavirus in the sera collected from mice 2 weeks and 16 weeks after immunization with two injections of inactivated vaccine.

[0063] Fig.18 The results recorded in Example 23 of the present invention show the neutralization titer results of the sera collected from mice after the booster injection of the yeast-expressed dimer vaccine of the present invention against the pseudovirus of the prototype strain of the new coronavirus and a series of variant strains.

[0064] Fig.19 The results of neutralization titer of serum collected from mice 2 weeks after the third immunization with the immunogen recorded in Example 24 of the present invention against pseudoviruses of the prototype strain of the new coronavirus and a series of variant strains are shown.

[0065] Fig. 20 The results recorded in Example 24 of the present invention show the neutralization titer results of the serum collected from mice 3 days before infection (i.e., 8 weeks after the third immunization) against the pseudovirus of the new coronavirus variant EG.5.

[0066] Fig.21 The qPCR assay results of gRNA and sgRNA of EG.5 virus in the lung tissue of mice after infection are shown in Example 25 of the present invention.

[0067] Fig. 22 The results of lung tissue sections of mice after challenge with poison as described in Example 26 of the present invention are shown.

[0068] Fig.23 A schematic diagram showing the electron microscopic structure of the complex of the PB protein and CB6 Fab protein purified in Example 12 as described in Example 27 of the present invention.

[0069] Fig.24 The PB purified in Example 3 of the present invention is shown 0 The mass spectrometry identification results of the N-sugar side chains of the protein and the PB protein purified in Example 12 are as determined in Example 28.

[0070] Fig.25 The PB purified in Example 3 of the present invention is shown 0 The statistical results of the N-sugar side chain distribution of the protein and the PB protein purified in Example 12 were determined as described in Example 28. DETAILED DESCRIPTION

[0071] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0072] In addition, in order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can also be implemented without certain specific details. In some embodiments, raw materials, elements, methods, means, etc. well known to those skilled in the art are not described in detail, so as to highlight the main purpose of the present invention.

[0073] Unless explicitly stated otherwise, throughout the specification and claims, the term “comprise” or variations such as “include” or “comprising”, etc., will be understood to include the stated elements or components but not to exclude other elements or components.

[0074] In the following examples, the following general methods are involved.

[0075] Preparation of Pichia pastoris competent cells

[0076] The Pichia pastoris strain was inoculated into 50 ml YPD medium (10 g / L yeast extract, 20 g / L peptone, 20 g / L glucose) and cultured at 30°C and 220 r / min until OD 600 =1.3~1.5; centrifuge at 4℃, 5000g for 5min to collect the bacteria; add pre-cooled 9mL BEDS and 1mL 1M DTT to the collected bacteria, resuspend and mix, centrifuge at 4℃, 5000g for 5min, collect the bacteria, add 1mL pre-cooled BEDS to resuspend the cells, and obtain electroporation competent cells.

[0077] Shake flask fermentation induction of recombinant strains

[0078] Two single clones of the recombinant Pichia pastoris strain were randomly selected and inoculated into 5 mL YPD liquid medium, cultured at 30°C and 220 r / min in a shaking incubator for 48 h, centrifuged at 3000 r / min for 5 min, the supernatant was discarded, and the bacteria were collected and transferred to 25 mL BMMY induction medium (containing 10 g / L yeast extract and 20 g / L peptone, sterilized at 121°C for 20 min, and then 13.4 g / L YNB and 4 × 10 -4g / L biotin, 0.5% methanol), cultured at 30°C, 220r / min shaking; during this period, 0.5%-0.8% (V / V) methanol was added every 12h, samples were taken regularly, and the supernatant was centrifuged to detect protein expression. If the strain is a histidine-deficient strain, 0.04mg / mL of histidine needs to be added to the BMMY medium.

[0079] High-density fermentation induction of recombinant strains

[0080] Seed shake flask culture: add 200 μL of bacterial solution from the glycerol tube to 5 mL of YPD. After culturing for 12 h, inoculate into 50 mL of YPD medium at a 1% inoculum size and culture at 30°C and 220 r / min for 24 h.

[0081] High-density fermentation culture: BMGY (containing 10 g / L yeast extract, 20 g / L peptone, and 40 g / L glycerol) was sterilized at 115°C for 20 min, and then 13.4 g / L YNB, 4×10 -4 The bacterial solution in 1L automatic fermentation tank was inoculated with 6% of 1g / L biotin, and the pH was controlled at 6.0 with ammonia water, the temperature was 30°C, the stirring speed was adjusted to 600-950rpm, and the ventilation volume was 2vvm. When the glycerol was exhausted (the dissolved oxygen rose rapidly), methanol was added after the bacteria were starved for 0.5-1.5h to start inducing the expression of recombinant protein. The methanol in the tank was maintained at 3g / L by automatic flow addition.

[0082] Example 1. Design of RBD dimer expression vector suitable for Pichia pastoris expression system

[0083] In the following examples, the Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα (whose nucleic acid sequence is shown in SEQ ID NO: 5) was used as a vector to construct an expression plasmid for the SARS-CoV-2 RBD dimer antigen.

[0084] The expression vector pMPICZα contains the coding sequences of AOX promoter, α-mating factor signal, Kex2 protease recognition site, multiple cloning site, C-terminal His tag, AOX terminator and other elements; during construction, the SARS-CoV-2RBD dimer fragment was connected to the multiple cloning site of the vector pMPICZα by double digestion with XhoI / NotI to complete the vector construction. In order to facilitate the acquisition of RBD dimer protein, 6xHis was also designed at the C-terminus of the protein as a purification tag. In addition, considering the codon preference of Pichia pastoris, the nucleotide sequence of the RBD dimer protein was also codon optimized.

[0085] Sequence synthesis and vector construction were completed by Nanjing GenScript Co., Ltd.

[0086] Example 2. Construction of yeast strains expressing SARS-CoV-2 prototype strain RBD dimer and prototype-Beta chimeric RBD dimer protein based on wild-type Pichia pastoris

[0087] 1. Preparation of Pichia pastoris competent cells

[0088] According to the above-mentioned procedure of “Preparation of Pichia competent cells”, Pichia competent cells for electrotransformation were prepared using Pichia strain GS115 (Invitrogen, Ca. 18100).

[0089] 2. Electroporation of recombinant expression plasmid into Pichia pastoris competent cells

[0090] According to the method of Example 1, the SARS-CoV-2 prototype strain RBD dimer (dimer of the 320-537th RBD segment, referred to as PP 0 ), Prototype-Beta chimeric RBD dimer (dimer of RBD segment 320-537, referred to as PB 0 ) were respectively named pMPICZα-PP 0 -His, pMPICZα-PB 0 -His; among them, PP 0 The amino acid sequence of the RBD dimer is shown in SEQ ID NO:6, and the encoding nucleic acid sequence is shown in SEQ ID NO:7; 0 The amino acid sequence of the RBD dimer is shown in SEQ ID NO:8, and the encoding nucleic acid sequence is shown in SEQ ID NO:9.

[0091] Take the correctly constructed recombinant expression plasmid pMPICZα-PP 0 -His, pMPICZα-PB 0 -His, each about 4 μg, linearized by SacI enzyme digestion, and the linearized DNA fragment was recovered by gel recovery kit; the linearized DNA was mixed with 40 μL of GS115 competent cells prepared in step 1, and transferred to a pre-cooled 0.2 cm electroporation cup; an electroporation instrument from BIO-RAD, USA, was used to perform electroporation according to the preset Pichia parameters of the electroporation instrument; after the electroporation, 1 mL of pre-cooled 1 M sorbitol aqueous solution was immediately added to the electroporation cup, and then all the solution in the electroporation cup was transferred to a sterile centrifuge tube, incubated at 30°C for 1 hour, and then spread on a YPD plate added with 100 μg / mL bleomycin, and cultured upside down at 30°C for 2-4 days until colonies appeared.

[0092] Thus, the recombinant Pichia pastoris strain GS-PP containing the coding gene of the above RBD dimer protein was obtained.0 -His and GS-PB 0 -His.

[0093] Example 3. Recombinant yeast strain GS-PP based on wild-type Pichia pastoris 0 -His and GS-PB 0 Expression and production of -His dimer protein

[0094] According to the above-mentioned "high-density fermentation induction of recombinant strains" procedure, the recombinant Pichia pastoris strain GS-PP constructed in Example 2 was 0 -His and GS-PB 0 -His was induced by high-density fermentation; after 90 h of methanol-induced expression, the fermentation was terminated, the precipitate was removed by centrifugation, and the supernatant was filtered through a 0.22 μm filter membrane to further remove impurities; the obtained cell supernatant was adsorbed through a nickel affinity column (His Trap, GE Healthcare) at 4°C and washed with buffer A (8 mM Na 2 HPO 4 , 136 mM NaCl, 2 mM KH 2 PO 4 , 2.6 mM KCl, pH 7.4) to remove nonspecific binding proteins, and then washed with buffer B (8 mM Na 2 HPO 4 , 136 mM NaCl, 2 mM KH 2 PO 4 , 2.6 mM KCl, 300 mM imidazole) to elute the target protein from His Trap, and collect the eluate at the elution peak for subsequent molecular sieve chromatography and SDS-PAGE identification of the target protein.

[0095] The eluate collected from the elution peak was concentrated with a 10 kD concentrator and replaced with molecular sieve chromatography buffer PBS (8 mM Na 2 HPO 4 , 136 mM NaCl, 2 mM KH 2 PO 4 , 2.6 mM KCl, pH 7.4), with a final volume of less than 1 ml; and then molecular sieve chromatography was performed using a HiLoadTM 16 / 600SuperdexTM 200 pg column (GE Healthcare) to further purify the target protein; during the chromatography, the eluate at the elution peak was collected for SDS-PAGE identification of the target protein.

[0096] RBD dimer protein PP 0 PB 0The molecular sieve chromatography curve and SDS-PAGE identification results of its elution peak are as follows Figure 1 As shown; Figure 1 PP 0 PB 0 In the molecular sieve chromatography curve, the arrow indicates the elution peak corresponding to the target protein; Figure 1 In the SDS-PAGE identification results of the elution peak, the SDS-PAGE electrophoresis results of the target protein eluate with or without the addition of PNGaseF deglycosylation enzyme are shown above the lane, which shows that: in the target protein eluate without the addition of PNGaseF deglycosylation enzyme, the eluted protein PP 0 and PB 0 All of them are diffuse, which suggests that the expressed dimer protein PP 0 and PB 0 However, after adding PNGaseF deglycosylation enzyme, the protein band was single and the size was also the size of a dimer, which shows that the heterogeneity of the purified dimeric protein was mainly caused by the heterogeneous glycosylation modification; that is, the RBD dimer protein expressed in the wild-type Pichia pastoris expression system has the defect of heterogeneous glycosylation modification.

[0097] Example 4. Construction of SARS-CoV-2 PB based on glycosylation engineered strain GSΔoch1 0 Recombinant yeast strains

[0098] In yeast, the polymannan reaction is catalyzed by a variety of glycosidases, among which the α-1,6 mannan transferase encoded by the gene OCH1 is responsible for initiating the polymannan reaction. In this example, according to the method of the document Enhancement of the Gene Targeting Efficiency of Non-Conventional Yeasts by Increasing Genetic Redundancy, PLoS ONE, 2013, the och1 gene of the Pichia pastoris strain GS115 was knocked out to construct the GSΔoch1 strain.

[0099] According to the above-mentioned "Preparation of Pichia pastoris competent cells" procedure, competent cells of GSΔoch1 strain were prepared; and according to the procedure described in Example 2, SARS-CoV-2PB 0 The recombinant expression plasmid (whose amino acid sequence and encoding nucleic acid sequence are the same as those described in Example 2) was linearized and electroporated into competent cells of GSΔoch1 strain to obtain GSΔoch1-PB 0 -His engineered strains.

[0100] Example 5. GSΔoch1-PB0 -His engineering strain shake flask fermentation induction and protein expression detection

[0101] According to the above-mentioned "shake flask fermentation induction of recombinant strains" procedure, the engineered strain GSΔoch1-PB constructed in Example 4 was 0 -His randomly selected two monoclones, inoculated them into BMMY medium, induced protein expression, and sampled them every 24 h. The OD value of the bacterial solution at 600 nm (i.e., OD 600 ), the strain growth curve is as follows Figure 2 At the same time, the fermentation liquid was collected for 72 hours, and the supernatant was collected. The expression of the target protein was detected by Western blot. The primary antibody was a whole antibody isolated from the immunized rabbit serum using the monomeric protein of the SARS-CoV-2 prototype strain RBD (319-537) derived from mammalian cell 293F. The secondary antibody was an HRP-labeled anti-rabbit antibody. The Western blot results are shown in Figure 2. Figure 2 shown.

[0102] Figure 2 The results showed that the engineered strain GSΔoch1-PB 0 -His growth was poor, and in the Western blot results of the 72h fermentation broth sample, clear dimer bands were seen, as well as monomer bands; this indicates that the engineered strain GSΔoch1-PB 0 -His expressed PB 0 In the dimeric protein, some dimers broke apart and produced monomers.

[0103] Example 6. Construction of GSΔoch1pAO strain

[0104] Based on the GSΔoch1 strain constructed in Example 4, the GSΔoch1pAO strain of the present invention was constructed in the hope of obtaining a non-defective strain, thereby improving the growth of the strain; that is, by molecular biological means, the pAOαM vector (whose sequence is shown in SEQ ID NO: 10) containing the histidinol dehydrogenase gene (HIS4) was integrated into the defective HIS4 gene position of the yeast strain GSΔoch1, thereby achieving the complementation of the histidine deficiency and obtaining the GSΔoch1pAO strain.

[0105] Specifically, the vector pAO containing the histidinol dehydrogenase encoding gene was linearized by SalI enzyme digestion, and the linearized DNA fragment was recovered; according to the method described in Example 2, the recovered linearized DNA fragment was electroporated into the competent cells of the Pichia pastoris strain GSΔoch1 (as prepared in Example 4), and the solution in the electroporation cup was revived for 1 hour and then all applied to the SD culture dish (the culture medium in the SD culture dish was composed of: YNB 13.4 g / L, biotin 0.4 mg / L, glucose 20 g / L, agar powder 20 g / L), and the histidine-deficient complementing strain was screened to obtain the GSΔoch1pAO engineered strain.

[0106] Example 7. Construction of SARS-CoV-2 PB based on glycosylation engineered strain GSΔoch1pAO 0 Protein recombinant yeast strains

[0107] According to the above-mentioned "Preparation of Pichia pastoris competent cells" procedure, competent cells of GSΔoch1pAO strain were prepared; and according to the procedure described in Example 2, SARS-CoV-2PB 0 The recombinant expression plasmid of the dimer (amino acid sequence and encoding nucleic acid sequence are the same as those described in Example 2) was linearized and electroporated into competent cells of the GSΔoch1pAO strain to obtain GSΔoch1pAO-PB 0 -His engineered strains.

[0108] Example 8. GSΔoch1pAO-PB 0 -His strain shake flask fermentation induction and protein expression detection

[0109] According to the above-mentioned "shake flask fermentation induction of recombinant strains" procedure, the engineered strain GSΔoch1pAO-PB obtained in Example 7 was 0 -His randomly selected two monoclones and inoculated them into BMMY medium to induce protein expression. Samples were taken every 24 h and the OD value of the bacterial solution at 600 nm (i.e., OD 600 ), the strain growth curve is as follows Figure 3 At the same time, the fermentation broth was collected for 72 hours, and the supernatant was collected. The protein expression was detected according to the Western blot procedure in Example 5. The results are as follows Figure 3 shown.

[0110] Figure 3 The results showed that compared with the engineered strain GSΔoch1-PB 0 -His (its growth curve is as Figure 2 ), strain GSΔoch1pAO-PB 0-His growth was significantly improved; and in the Western blot results of the 72h fermentation broth sample, a clear, single dimer band was seen, and there was also a monomer band; this shows that the engineered strain GSΔoch1pAO-PB 0 -His expressed PB 0 The dimeric protein is relatively uniform (including relatively uniform glycosylation modification), however, some of the dimeric proteins are broken to form monomers (indicating that their expression is unstable).

[0111] Example 9. Engineering strain GSΔoch1pAO-PB 0 High-density fermentation induction of -His and acquisition of dimeric protein

[0112] According to the above-mentioned "high-density fermentation induction of recombinant strains" procedure, the engineered strain GSΔoch1pAO-PB obtained in Example 7 was 0 -His was fermented at high density, and the purified RBD dimer protein PB was obtained according to the method in Example 3. 0 The molecular sieve chromatography curve and SDS-PAGE identification results of its elution peak are as follows Figure 4 shown.

[0113] Depend on Figure 4 It can be seen that during the molecular sieve chromatography, two elution peaks were generated, namely, peak 1 and peak 2; the SDS-PAGE electrophoresis results of the two peaks showed that the eluate corresponding to peak 1 contained both dimer and monomer proteins, while the eluate corresponding to peak 2 contained only monomer proteins; this may be because: during molecular sieve chromatography, elution peaks 1 and 2 corresponded to dimer proteins and monomer proteins, respectively, but since the dimer protein in elution peak 1 was unstable, some of the dimer proteins broke to produce monomers after elution and before SDS-PAGE electrophoresis, thus forming a mixture of dimers and monomers. In short, the engineered strain GSΔoch1pAO-PB 0 -His high-density fermentation induction failed to obtain a stable dimeric protein; N-terminal sequencing results confirmed that: in PB 0 A break occurred between the 328R / 329F dimers.

[0114] The above results show that the expression of PB in the GSΔoch1pAO yeast system 0 The dimer has a relatively uniform glycosylation, so the glycosylation engineering strain was used to solve the problem of uneven glycosylation; however, PB 0 The presence of monomers in dimers indicates that PB 0 The dimer could not be stably expressed in the GSΔoch1pAO yeast system.

[0115] Example 10. Construction of recombinant yeast strains of different prototype-Beta chimeric RBD dimer proteins based on the glycosylation engineering strain GSΔoch1pAO

[0116] In order to achieve stable expression of dimeric proteins, 6 different construction schemes were designed according to the break position. The specific construction schemes are as follows: Figure 5 As shown in A; Figure 5 In A, PB represents the SARS-CoV-2 prototype-Beta chimeric RBD dimer (dimer of RBD segments 329-537), and GS, De, GSGS, DeGS, and R328-De are in PB. 0 The PB obtained by performing specific site mutations as shown in the figure 0 Mutant sequence; specifically, the amino acid sequence of the RBD dimer of PB is shown in SEQ ID NO:1, and its encoding nucleic acid sequence is shown in SEQ ID NO:2.

[0117] According to the design of Example 1, 6 recombinant expression plasmids were obtained respectively, and according to the procedures of the previous examples, the recombinant expression plasmids were linearized and transformed into the strain GSΔoch1pAO to obtain the yeast engineering strains GS, De, GSGS, DeGS, R328-De, and PB.

[0118] Example 11. Testing protein expression of engineered strains with different prototype-Beta chimeric RBD sequences at the shake flask level

[0119] Two clones were randomly selected from each of the engineered strains obtained in Example 10, and shake flask fermentation was performed according to the above-mentioned "Shake flask fermentation induction of recombinant strains" procedure. After fermentation for 72 hours, the bacterial liquid was taken and centrifuged to obtain the supernatant. The expression of the dimer protein was detected according to the Western blot procedure described in Example 5. The results are as follows: Figure 5 As shown in B.

[0120] Depend on Figure 5 B shows that among the six engineered strains, the dimeric proteins expressed by the GS and De strains still have a large number of breaks into monomers, the protein yields expressed by the GSGS and DeGS strains are extremely low, and the dimeric proteins expressed by the R328-De strain still have some breaks into monomers. In contrast, in the expression of the PB strain, almost all are dimeric proteins, and the dimeric protein bands are relatively clear and single (as shown by the solid arrows), and the protein yield is high, which shows that the PB engineered strain can stably express the dimeric protein PB (i.e., the dimer of the 329-537 RBD segment), and the expressed dimeric protein PB is uniform in form (including relatively uniform glycosylation modification) and has a high yield.

[0121] Example 12. Obtaining a homogeneously glycosylated and stable dimeric prototype-Beta protein (PB for short)

[0122] According to the above-mentioned "high-density fermentation induction of recombinant strains", the engineered strain obtained in Example 11 was subjected to high-density fermentation, and according to the method in Example 3, the purified RBD dimer protein PB was obtained through SuperdexTM200 Increase 10 / 300GL molecular sieve. The molecular sieve chromatography curve and SDS-PAGE identification results of its elution peak are as follows: Figure 6 shown.

[0123] Depend on Figure 6 It can be seen that a stable PB dimer protein with uniform glycosylation (ie, a dimer of the RBD segment at positions 329-537) was obtained.

[0124] Example 13. Obtaining the uniformly glycosylated and stable dimeric Delta-Omicron (BA.1) protein (abbreviated as D-BA.1)

[0125] The method for constructing PB in Example 10 was used to construct an engineered strain D-BA.1 expressing Delta-Omicron (BA.1) RBD dimer protein, wherein the Delta-Omicron (BA.1) RBD dimer is a dimer of the 329-537 RBD segment of the Delta variant and the 329-537 RBD segment of the Omicron (BA.1) variant, and its amino acid sequence is shown in SEQ ID NO: 3, and its encoding nucleic acid sequence is shown in SEQ ID NO: 4; then, according to the methods of Examples 11 and 12, the engineered strain was fermented and the protein was purified. The molecular sieve chromatography curve and the SDS-PAGE identification results of its elution peak are shown in Figure 7 shown by Figure 7 It was found that a stable D-BA.1 dimer protein with uniform glycosylation was obtained.

[0126] As described above, the present invention has developed a modified Pichia pastoris, and a method for expressing the SARS-CoV-2 RBD dimer protein in the yeast strain to prepare a SARS-CoV-2 vaccine antigen; using the modified Pichia pastoris strain, it is possible to achieve: (1) stable expression and high yield of specific RBD dimer protein antigens; (2) uniform glycosylation of the expressed antigen protein; and (3) stable conformation of the antigen protein, which has strong application value as a vaccine antigen.

[0127] Because the epidemic variants of the new coronavirus change rapidly and some variants show strong immune escape, we used the above method to design a series of immunogens for vaccine preparation and experiments, proving the universality of this method.

[0128] Example 14. Detection of humoral immune response induced by RBD dimer protein

[0129] In order to detect the immunogenicity of various chimeric RBD-dimer proteins obtained in the above examples, we used the dimer proteins PB and D-BA.1 obtained in Examples 12 and 13 as immunogens to immunize BALB / c mice respectively, and the negative control (Sham group) was immunized with PBS solution, with 10 mice in each group. The BALB / c mice used were purchased from Vital River Company, all female, 6-8 weeks old. The mouse grouping and immunization dose are shown in Table 1.

[0130] Table 1. Grouping and immunization dose of mice immunized with SARS-CoV-2 RBD dimer protein

[0131]

[0132] The specific immunization procedure is as follows: the immunogen is diluted to 40 μg / ml with PBS, and the diluted immunogen is mixed and emulsified with AddaVax adjuvant (a vaccine adjuvant similar to MF59) at a volume ratio of 1:1 to prepare a vaccine; among them, the sham group is a mixture of PBS solution and AddaVax adjuvant to prepare a vaccine control. The obtained vaccine was immunized to BALB / c mice by intramuscular injection. All mice were immunized for the first, second, and third time on days 0, 21, and 42, respectively, with an inoculation volume of 100 μL each time (containing 2 μg of antigen protein); on days 40 and 56, the mice were bled, and the serum was collected by centrifugation, and the obtained serum was stored in a refrigerator at -80°C.

[0133] The antigen-specific antibody titer induced by the vaccine in BALB / c mice was detected by ELISA. The specific detection procedure is as follows:

[0134] (1) Dilute the RBD of the new coronavirus to 3 μg / ml with ELISA coating solution (Solabo, C1050), add 100 μL of the corresponding RBD protein dilution solution to each well of a 96-well ELISA plate (Corning, 3590), and place at 4°C for 12 hours;

[0135] (2) Pour off the coating solution, add PBS, and wash once; use 5% skim milk prepared in PBS as blocking solution, add it to a 96-well plate, 100 μL per well, and leave it at room temperature for 1 hour for blocking; after blocking, wash once with PBS solution;

[0136] (3) During the blocking period, the immune mouse serum was diluted with blocking solution. Specifically, starting from 20 times, the serum was diluted in a 4-fold gradient. Then, 100 μL of the diluent was added to each well of the ELISA plate, and the negative control was added with blocking solution. The plates were incubated at 37°C for 2 hours, and then washed 4 times with PBST (PBS containing 1 / 1000 Tween-20).

[0137] (4) Add HRP-conjugated goat anti-mouse secondary antibody (Abcam, ab6789) diluted 1:2000 with blocking solution, incubate at 37°C for 1.5 hours, then wash 5-6 times with PBST; add 60 μL TMB colorimetric solution for color development, add 60 μL 2M hydrochloric acid to terminate the reaction after an appropriate reaction time, and then detect OD on an ELISA reader. 450 Reading value;

[0138] The antibody titer value is defined as the highest serum dilution factor with a reaction value greater than 2.5 times the negative control value. When the reaction value of the lowest dilution factor (detection limit) is still less than 2.5 times the background value, the titer of the sample is defined as half of the lowest dilution factor, i.e. 1:10;

[0139] The antigen-specific antibody titers in the serum after the second immunization and the serum after the third immunization were detected by the ELISA procedure. Figure 8 shown by Figure 8 It can be seen that the SARS-CoV-2 RBD dimers PB and D-BA.1 based on the modified Pichia pastoris of the present invention can activate the body to produce higher levels of antibodies, especially after three immunizations, the antibody level is further enhanced.

[0140] Example 15. Neutralization experiment of novel coronavirus pseudovirus to detect the neutralizing antibody titer induced by vaccine in BALB / c mice

[0141] Using the new coronavirus pseudovirus, the 50% pseudovirus neutralization titer (pVNT) of the collected triple-immunized mouse sera against the pseudovirus of the prototype strain and variant strain of the new coronavirus was tested. 50 ), among which the variants include Alpha, Beta, Delta, and Omicron variants.

[0142] The new coronavirus pseudovirus used in this example is a pseudovirus displaying the new coronavirus S protein prepared based on the vesicular stomatitis virus (VSV) backbone. For the preparation method, please refer to the method section of the paper that this research group has published publicly (Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant, N Engl J Med, 2022, PMID: 35081296).

[0143] The method for detecting the neutralizing antibody titer of the new coronavirus pseudovirus (hereinafter referred to as pseudovirus) is as follows:

[0144] In a 96-well plate, the immune mouse serum was diluted in a 2-fold gradient and then mixed with the pseudovirus respectively; at the same time, the blank culture medium was mixed with the pseudovirus as a control; then, the mixture was incubated at 37°C for 1 hour; thereafter, the immune serum / blank culture medium-pseudovirus mixture was transferred to a 96-well plate filled with Vero cells; 15 hours later, the fluorescence value was calculated by a CQ1 confocal cell imager (Yokogawa), and then a fitting curve was drawn in the GraphPad Prism software to calculate the reciprocal of the serum dilution corresponding to 50% neutralization, which is the 50% pseudovirus neutralization titer pVNT. 50 .

[0145] The results of the pseudovirus neutralizing antibody titer test for each immunogen are as follows Fig. 9 As shown by Fig. 9 It can be seen that:

[0146] 1) Regarding the prototype and Beta chimeric RBD-dimer (PB), the geometric mean (GMT) of the neutralizing antibody titers of the sera of mice immunized with the prototype, Beta, Delta, Omicron BA.2, Omicron BA.1 and Omicron BA.5 pseudoviruses were 8972, 14056, 4817, 1172, 2510 and 117, respectively;

[0147] 2) Regarding the Delta and Omicron chimeric RBD-dimer (D-BA.1), the geometric mean (GMT) of the neutralizing antibody titers of the immune mouse sera against the prototype strain pseudovirus, Beta strain pseudovirus, Delta strain pseudovirus, Omicron BA.2 strain pseudovirus, Omicron BA.1 strain pseudovirus and Omicron BA.5 strain pseudovirus were 8406, 10292, 26577, 19884, 46631 and 1800, respectively.

[0148] The above results indicate that the RBD dimer protein expressed by the recombinant Pichia pastoris engineered bacteria expressing the SARS-CoV-2 RBD dimer of the present invention can induce the production of a high level of neutralizing antibody titers.

[0149] Example 16. Obtaining the uniformly glycosylated and stable dimeric Delta-Omicron (BA.5) protein (abbreviated as D-BA.5)

[0150] The method for constructing PB in Example 12 was used to construct an engineered strain D-BA.5 expressing Delta-Omicron (BA.5) RBD dimer protein, wherein the Delta-Omicron (BA.5) RBD dimer is a dimer of the 329-537 RBD segment of the Delta variant and the 329-537 RBD segment of the Omicron (BA.5) variant, and its amino acid sequence is shown in SEQ ID NO: 11, and its encoding nucleic acid sequence is shown in SEQ ID NO: 12; then, according to the methods of Examples 11 and 12, the engineered strain was fermented and the protein was purified. The SDS-PAGE identification results of the elution peak were as shown. Fig.10 shown by Fig.10 It can be seen that a stable D-BA.5 dimer protein with uniform glycosylation was obtained.

[0151] Example 17. Obtaining the uniformly glycosylated and stable dimeric Delta-Omicron (BQ.1.1) protein (abbreviated as D-BQ.1.1)

[0152] The method for constructing PB in Example 12 was used to construct an engineered strain D-BQ.1.1 expressing Delta-Omicron (BQ.1.1) RBD dimer protein, wherein the Delta-Omicron (BQ.1.1) RBD dimer is a dimer of the 329-537 RBD segment of the Delta variant and the 329-537 RBD segment of the Omicron (BQ.1.1) variant, and its amino acid sequence is shown in SEQ ID NO: 13, and its encoding nucleic acid sequence is shown in SEQ ID NO: 14; then, according to the methods of Examples 11 and 12, the engineered strain was fermented and the protein was purified, and the SDS-PAGE identification results of the elution peak were as shown. Fig.11 shown by Fig.11 It can be seen that a stable D-BQ.1.1 dimer protein with uniform glycosylation was obtained.

[0153] Example 18. Obtaining the uniformly glycosylated and stable dimeric Delta-Omicron (XBB) protein (abbreviated as D-XBB)

[0154] The method for constructing PB in Example 12 was used to construct an engineered strain D-XBB expressing Delta-Omicron (XBB) RBD dimer protein, wherein the Delta-Omicron (XBB) RBD dimer is a dimer of the 329-537 RBD segment of the Delta variant and the 329-537 RBD segment of the Omicron (XBB) variant, and its amino acid sequence is shown in SEQ ID NO: 15, and its encoding nucleic acid sequence is shown in SEQ ID NO: 16; then, according to the methods of Examples 11 and 12, the engineered strain was fermented and the protein was purified, and the SDS-PAGE identification results of the elution peak were as shown. Fig.12 shown by Fig.12 It can be seen that a stable D-XBB dimer protein with uniform glycosylation was obtained.

[0155] Example 19. Obtaining the glycosylated homogeneous and stable dimer Omicron (XBB) - Omicron (BA.5) protein (abbreviated as XBB-BA.5)

[0156] The method for constructing PB in Example 12 was used to construct an engineered strain XBB-BA.5 expressing Omicron(XBB)-Omicron(BA.5)RBD dimer protein, wherein the Omicron(XBB)-Omicron(BA.5)RBD dimer is a dimer of the 329-537 RBD segment of the Omicron(XBB) variant and the 329-537 RBD segment of the Omicron(BA.5) variant, and its amino acid sequence is shown in SEQ ID NO:17, and its encoding nucleic acid sequence is shown in SEQ ID NO:18; then, according to the methods of Examples 11 and 12, the engineered strain was fermented and the protein was purified. The SDS-PAGE identification results of the elution peak were as shown in Fig.13 shown by Fig.13 It can be seen that a stable XBB-BA.5 dimer protein with uniform glycosylation was obtained.

[0157] Example 20. Detection of humoral immune response induced by RBD dimer protein

[0158] The humoral immune detection method in Example 14 was used to detect the immunogenicity of the chimeric RBD-dimer proteins obtained in Examples 16, 17, 18, and 19.

[0159] Specifically, the dimer proteins D-BA.5, D-BQ.1.1, D-XBB, and XBB-BA.5 obtained in Examples 16, 17, 18, and 19 were used as immunogens to immunize BALB / c mice, respectively, and the negative control (Sham group) was immunized with PBS solution plus AddaVax adjuvant, with 8 mice in each group. The BALB / c mice used were purchased from Vital River Company, all female, 6-8 weeks old. The mouse grouping and immunization dose are shown in Table 2.

[0160] Table 2. Grouping and immunization dose of mice immunized with SARS-CoV-2 RBD dimer protein

[0161]

[0162] Mice were immunized according to the immunization procedure in Example 14, and blood was collected on the 40th day (hereinafter referred to as "after the second immunization"), the 8th week (i.e., two weeks after the third immunization, hereinafter referred to as "after the third immunization"), and the 22nd week (i.e., 16 weeks after the third immunization, hereinafter referred to as "16 weeks after the third immunization") for later use.

[0163] The ELISA method in Example 14 was used to detect the antigen-specific antibody titer induced by the vaccine in BALB / c mice.

[0164] The results of antigen-specific antibody titers in mouse sera after the second and third immunizations are as follows: Fig.14 shown by Fig.14 It can be seen that the SARS-CoV-2 RBD dimers D-BA.5, D-BQ.1.1, D-XBB, and XBB-BA.5 based on the modified Pichia pastoris of the present invention can activate the body to produce higher levels of binding antibodies, especially after three immunizations, the level of binding antibodies is further enhanced.

[0165] Example 21. Neutralization experiment of novel coronavirus pseudovirus to detect the neutralizing antibody titer induced by vaccine in BALB / c mice

[0166] The method described in Example 15 was used to detect the 50% pseudovirus neutralization titer (pVNT) of the collected mouse sera after three immunizations against the pseudoviruses of the prototype strain and variant strains of the new coronavirus Beta, Delta, Omicron BA.2, Omicron BA.5, OmicronBF.7, Omicron BQ.1.1, Omicron XBB, Omicron EG.5.1 and Omicron BA.2.86. 50 ).

[0167] The results of the pseudovirus neutralizing antibody titer test for each immunogen are as follows Fig.15 As shown by Fig.15 It can be seen that:

[0168] 1) Regarding the Delta and Omicron chimeric RBD-dimer (D-BA.5), the geometric mean (GMT) of neutralizing antibody titers of the sera of mice immuned with the prototype strain, Beta strain, Delta strain, Omicron BA.2 strain, Omicron BA.5 strain, Omicron BF.7 strain, Omicron BQ.1.1 strain, Omicron XBB strain, Omicron EG.5.1 and Omicron BA.2.86 strain pseudovirus were 731, 533, 3808, 1176, 10311, 2602, 414, 54, 71 and 155, respectively;

[0169] 2) Regarding Delta and Omicron chimeric RBD-dimer (D-XBB), the geometric mean (GMT) of neutralizing antibody titers of sera from mice immunized with the prototype strain, Beta strain, Delta strain, Omicron BA.2 strain, Omicron BA.5 strain, Omicron BF.7 strain, OmicronBQ.1.1 strain, Omicron XBB strain, Omicron EG.5.1 and Omicron BA.2.86 strain pseudovirus were 1438, 629, 3678, 969, 372, 474, 162, 1814, 322 and 731, respectively;

[0170] 3) Regarding the Delta and Omicron chimeric RBD-dimer (D-BQ.1.1), the geometric mean (GMT) of neutralizing antibody titers of the sera of mice immunized therewith against the prototype strain, Beta strain, Delta strain, Omicron BA.2 strain, Omicron BA.5 strain, Omicron BF.7 strain, OmicronBQ.1.1 strain, Omicron XBB strain, Omicron EG.5.1 and Omicron BA.2.86 strain pseudovirus were 569, 294, 4201, 2960, 12378, 8901, 20535, 48, 153 and 389, respectively;

[0171] 4) Regarding Omicron (XBB) and Omicron (BA.5) chimeric RBD-dimer (XBB-BA.5), the geometric mean (GMT) of the neutralizing antibody titers of the immune mouse sera against the prototype strain, Beta strain, Delta strain, Omicron BA.2 strain, Omicron BA.5 strain, Omicron BF.7 strain, Omicron BQ.1.1 strain, Omicron XBB strain, Omicron EG.5.1 and Omicron BA.2.86 strain pseudovirus were 296, 174, 414, 4400, 19151, 20364, 7773, 3707, 1600 and 651, respectively.

[0172] Example 22. Neutralization experiment of novel coronavirus pseudovirus to detect the neutralizing antibody titer of the serum of BALB / c mice 16 weeks after three immunizations induced by vaccine

[0173] The method described in Example 15 was used to detect the 50% pseudovirus neutralization titer (pVNT) of the pseudoviruses of the prototype strain and variant strains of the new coronavirus Beta, Delta, Omicron BA.2, Omicron BA.5, Omicron BF.7, Omicron BQ.1.1, Omicron XBB, OmicronEG.5.1 and Omicron BA.2.86 of the sera collected 16 weeks after the three immunizations in the Sham, D-XBB and XBB-BA.5 groups respectively. 50 ).

[0174] The results of the pseudovirus neutralizing antibody titer test of the serum after three immunizations of the above-mentioned immunogens (corresponding to "8w" in the figure) and the serum 16 weeks after three immunizations (corresponding to "22w" in the figure) are as follows Fig.16 As shown by Fig.16 It can be seen that 16 weeks after the mice completed the three-injection sequential immunization, the titer levels of pseudovirus neutralizing antibodies of each immunogen were basically consistent with the titer levels of the serum after the three immunizations.

[0175] The above results indicate that the RBD dimer protein expressed by the recombinant Pichia pastoris expressing the SARS-CoV-2 RBD dimer of the present invention induces the production of high levels of neutralizing antibodies, and this high level of neutralizing antibody titer can be maintained for a long time.

[0176] Example 23. Neutralizing antibody titers induced by yeast RBD dimer vaccine as a booster shot in BALB / c mice

[0177] In order to detect the immune protection effect of yeast dimer RBD vaccine as a booster shot, we used the dimer proteins D-BA.5, D-XBB and XBB-BA.5 obtained in Examples 16, 18 and 19 as immunogens to immunize BALB / c mice respectively, and the negative control (Sham group) was immunized with PBS solution plus AddaVax adjuvant. The BALB / c mice used were purchased from Vital River Company, all female, 6-8 weeks old.

[0178] The specific immunization procedure is as follows: the vaccine is immunized to BALB / c mice by intramuscular injection. All mice are immunized for the first, second and third time on the 0th day, the 21st day and the 133rd day respectively. The first two injections are inactivated vaccines (BBIBP-CorV, Sinopharm Group China Biological Beijing Company), and the third injection (i.e., booster injection) is the yeast-expressed dimer vaccine of the present invention, with an inoculation volume of 100 μL each time (containing 2 μg of antigen protein); the control group is the inactivated vaccine for the third injection. Blood was collected from mice 2 weeks after the second immunization, 16 weeks after the second immunization and 2 weeks after the third immunization, and serum was collected by centrifugation. The obtained serum was stored in a refrigerator at -80°C.

[0179] The method described in Example 15 was used to detect the neutralization titer of the collected mouse sera after two immunizations against the pseudovirus of the new coronavirus prototype strain, and the 50% pseudovirus neutralization titer (pVNT) of the mouse sera after three immunizations against the pseudovirus of the new coronavirus prototype strain and variants Beta, Delta, Omicron BA.2, Omicron BA.5, Omicron BF.7, Omicron BQ.1.1, Omicron XBB, Omicron EG.5.1 and Omicron BA.2.86. 50 ).

[0180] The results of the neutralizing antibody titer test of mouse sera against the pseudovirus of the prototype strain of the new coronavirus are as follows: Fig.17 As shown, Fig.17 It shows that after two injections of inactivated vaccine, mice gained protection against the pseudovirus of the prototype strain of the new coronavirus.

[0181] After boosting (i.e., triple immunization) with the yeast-expressed dimer vaccine of the present invention, the neutralizing antibody titer test results of mouse serum against the prototype strain of the new coronavirus and the variant strains Beta, Delta, Omicron BA.2, Omicron BA.5, Omicron BF.7, OmicronBQ.1.1, Omicron XBB, Omicron EG.5.1 and Omicron BA.2.86 pseudovirus are as follows: Fig.18 As shown, Fig.18It was shown that compared with the control group of three injections of inactivated vaccine, the use of ZF2001 (Anhui Zhifei Longcoma Biopharmaceutical Co., Ltd.) and yeast-expressed dimer vaccine as booster injections can not only improve the neutralization ability against pseudoviruses but also increase the broad spectrum of neutralization against pseudoviruses, especially XBB-BA.5.

[0182] These results indicate that based on the basic immunization with the inactivated vaccine, using the yeast-expressed dimer vaccine of the present invention as a booster shot can effectively enhance the body's immune protection against the new coronavirus.

[0183] Example 24. Live virus challenge experiment

[0184] Experimental methods: In order to evaluate the protective efficacy of the candidate vaccine XBB-BA.5, the SARS-CoV-2 challenge protection experiment used the epidemic mutant strain EG.5.

[0185] The experiment was divided into Sham group and XBB-BA.5 group, with 6 mice in each group, and the immunization method was shown in Table 2 above; the specific immunization scheme was as follows: PBS and XBB-BA.5 were used to immunize a group of BALB / c mice (6-8 weeks old female, purchased from Viagra), respectively, and three doses of 2 μg XBB-BA.5 vaccine (using AddaVax adjuvant) were vaccinated (with an interval of 21 days) according to the time nodes in Example 15. Serum was collected 2 weeks after the three immunizations to detect the neutralizing antibody titer against Prototype, BA.5, BF.7, XBB, EG.5, and EG.5.1 pseudoviruses, and serum was collected 8 weeks after the three immunizations to detect the neutralizing antibody titer against EG.5 pseudovirus. The detection method referred to Example 21.

[0186] The results of the neutralizing antibody titers of the serum collected 2 weeks after the three immunizations against the above pseudoviruses are as follows: Fig.19 As shown, Fig.19 The results showed that compared with the Sham group, the levels of neutralizing antibodies against Prototype, BA.5, BF.7, XBB, EG.5, and EG.5.1 pseudoviruses in the serum of mice immunized with XBB-BA.5 were significantly increased, and the difference between the two was significant.

[0187] The results of the neutralizing antibody titer test against EG.5 pseudovirus in serum collected 8 weeks after the third immunization are as follows Fig. 20 As shown, Fig. 20 The results showed that compared with the Sham group, the level of neutralizing antibodies against EG.5 pseudovirus in the serum of mice immunized with XBB-BA.5 was significantly increased, and the difference between the two was extremely significant.

[0188] Next, the Omicron EG.5 strain was used to challenge the immune mice with the new coronavirus through nasal drops. All challenge-related experiments were completed in an ABSL-3 laboratory. The challenge strain information and dose are as follows: Omicron EG.5 (NPRC2.192100031) challenge dose is 2.5×10 4 TCID 50 On the third day after infection, the mice were euthanized, and then the lung tissues of the infected mice were collected and divided into two parts, one of which was placed in 4% paraformaldehyde for lung tissue section analysis. The remaining samples were stored in a -80°C refrigerator for later RNA extraction and viral load determination.

[0189] Example 25. Determination of virus titer in lung tissue after challenge

[0190] In this example, RNA was extracted from the lung tissues of the XBB-BA.5 immunized mice and the Sham group mice after challenge with the live virus of the new coronavirus in Example 24, and a SARS-CoV-2-specific quantitative PCR (qRT-PCR) assay was performed on a CFX96 Touch real-time PCR detection system (Bio-Rad, USA) using an RT-qPCR kit (Tiangen Biotech, China, catalog number: FP314). Specifically, a specific region of the N gene and a specific sequence of the E gene of the viral genome were detected (for details, please see Chandrashekar, A., et al., SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, 2020. 369(6505): p. 812-817).

[0191] RNA extraction (ABSL-3 laboratory):

[0192] The lung sample was ground, and 200 μL of the supernatant after grinding was added to the lysis solution (500 μL) of the RNA extraction kit and mixed well. The virus was inactivated. Then RNA was extracted according to the instructions of the MagaBio plus viral RNA extraction kit; the extracted RNA was stored in a -80°C refrigerator for later use.

[0193] (1) qPCR experiment: The following primers and probes (Table 3) were used to detect the gRNA and sgRNA levels of the viral genome of Omicron EG.5; gRNA represents the load of the infected virus, and sgRNA represents the load of the replicating virus;

[0194] Table 3. qPCR primer and probe sequences

[0195]

[0196] According to Tables 4 and 5 below, the qPCR system was configured and the qPCR program was set.

[0197] Table 4. qPCR system configuration

[0198] Reagents System (μL) 2XqPCR 10 25FastKing Enzyme Mix 0.8 F 0.5 R 0.5 Probe 0.4 <![CDATA[ddH 2 The]]> 2.8 Template RNA 5 System volume 20

[0199] Table 5. qPCR program

[0200]

[0201]

[0202] The qPCR detection results of viral gRNA and sgRNA in mouse lung samples are as follows Fig.21 As shown; Fig.21 The results showed that the levels of viral gRNA and sgRNA in the lungs of the XBB-BA.5 immunized mice were significantly lower than those of the PBS group, and the sgRNA of the immunized mice was even below the detection line, indicating that the XBB-BA.5 vaccine completely inhibited the replication of the virus.

[0203] From the above experimental results, it can be concluded that XBB-BA.5 as an immunogen can effectively reduce the viral load in the lungs of mice immunized with live virus in the live virus challenge experiment, and at the same time can inhibit the replication of the virus, showing a good protective effect against the popular new coronavirus variant EG.5.

[0204] Example 26. Histopathological analysis of lungs after challenge

[0205] In this example, the mouse lung tissue collected in Example 25 was fixed, dehydrated, paraffin-embedded, and sliced; the tissue sections (4 μm) were dewaxed in xylene and pathologically examined by hematoxylin and eosin (HE) staining.

[0206] The results are as follows Fig. 22 As shown. Fig. 22 It can be seen that mice immunized with XBB-BA.5 vaccine showed milder pneumonia symptoms, reduced lung hemorrhage and inflammatory cell infiltration, indicating that the vaccine has a good protective effect on mice.

[0207] Example 27. Electron microscopic structure analysis of the PB and CB6 Fab complex

[0208] The PB dimer protein prepared in Example 12 was mixed with the CB6 Fab protein and incubated at 4°C for 2 hours. Then, molecular sieve chromatography (pH 7.4) was performed using a SuperdexTM200 Increase 10 / 300GL column (GE Healthcare). The eluted peak was identified by SDS-PAGE. The SDS-PAGE identification results showed that the eluted peak was a complex of the PB protein and CB6Fab, thereby confirming that a complex protein of the PB dimer protein and CB6Fab was obtained. The sample was used for electron microscopy structure analysis.

[0209] Prepare the Quantifoil grid (specification 1.2 / 1.3) for sample preparation in advance and perform glow discharge hydrophilization treatment.

[0210] The prepared complex of PB dimer protein and CB6 Fab was then dripped onto the prepared grid, and the grid was quickly inserted into liquid ethane using the automatic sample preparation machine Vitrobot Mark IV to complete the sample preparation. Data collection was performed using a 300kV Titan Krios transmission electron microscope (Thermo Fisher) with a K3 direct electron detector camera, and a large number of photos were collected using the Serial-EM automatic collection program. Then, the collected raw data were drift corrected using MotionCor2 software, the images were contrast-transfer-function corrected using CTFFIND4.1 software, and the images were further processed and finally reconstructed in three dimensions using Relion-3.1 software.

[0211] Cryo-EM images of the complex of PB dimer and CB6 Fab Fig.23 As shown by Fig.23 It can be seen that the PB dimer is approximately in the shape of a "double lung", in which the Prototype RBD can bind to the CB6 Fab, which shows that the PB dimer protein can expose important immune epitopes, thereby stimulating the specific immune response of mice.

[0212] Example 28. PB 0 and PB protein N-glycan mass spectrometry sample preparation

[0213] PB expressed by wild-type yeast 0The protein sample (prepared as in Example 3) and the PB protein sample expressed by the glycosylation engineering strain GSΔoch1pAO (prepared as in Example 12) were added with an appropriate amount of N-glycosidase (PNGaseF), placed in a 37°C water bath overnight to release N-glycans, and then 500uL of 5% acetonitrile solution containing 0.01% trifluoroacetic acid was added to the sample mixed solution, and the N-glycans in the mixed solution were extracted using a solid phase extraction method based on porous graphitized carbon (PGC), and after formiamide derivatization, the N-glycans after the derivatization reaction were purified using a solid phase extraction method based on hydrophilic chromatography. The purified N-glycans were detected in the reflected positive ion mode of the MALDI-TOF-MS mass spectrometer. The N-glycans were first dissolved with 10uL of 50% acetonitrile solution. 0.5uL of the sample was spotted in a small hole on a stainless steel MALDI plate, and then the same volume of 10mg / mL DHB matrix containing 10mM sodium acetate was spotted to ensure that the glycans were ionized in the form of sodium adducts. According to the mass of N-glycans, a total of 1000 laser irradiations were performed at a laser frequency of 2000Hz, and the mass range of detection was set to 1000-3000Da, with 1000 laser irradiations per sample point. The mass spectrometry data were baseline corrected, noise filtered, and peak deisotoped in Data Explorer software (Applied Biosystems).

[0214] PB 0 The results of mass spectrometry identification of N-glycans of PB proteins are as follows Fig.24 The corresponding percentage analysis results are shown in Fig.25 As shown; Fig.24 and Fig.25 Display, PB 0 The sugar chain of PB protein is relatively broad (i.e., man4-man16), in which the main glycoside types are man9 and man10, accounting for 33.81% and 36.3% respectively; while the sugar chain structure of PB protein is relatively narrow (i.e., man6-man15), in which the main glycoside types are man8 and man9, accounting for 46.29% and 24.85% respectively. This shows that compared with the PB expressed by wild-type yeast strains, 0 Protein, the PB protein expressed by the glycosylation engineering strain GSΔoch1pAO can effectively reduce the types of sugar chains and increase the uniformity of protein glycosylation modification.

[0215] In summary, the recombinant Pichia pastoris expressing the SARS-CoV-2 RBD dimer of the present invention can not only efficiently express the SARS-CoV-2 RBD dimer protein with uniform glycosylation and stability, but the expressed RBD dimer protein can also induce a strong humoral immune response and produce a high level of neutralizing antibody titer, which has great cost-effectiveness and practical significance.

[0216] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the present invention.

[0217] Sequences involved in this application:

[0218] Amino acid sequence of PB (SEQ ID NO: 1)

[0219] FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGC VIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0220] PB encoding nucleic acid sequence (SEQ ID NO: 2)

[0221]

[0222] Amino acid sequence of D-BA.1 (SEQ ID NO: 3)

[0223] FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0224] The encoding nucleic acid sequence of D-BA.1 (SEQ ID NO: 4)

[0225]

[0226] pMPICZα sequence (SEQ ID NO:5)

[0227]

[0228] PP 0 Amino acid sequence (SEQ ID NO:6)

[0229] VQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0230] PP 0 The encoding nucleic acid sequence (SEQ ID NO:7)

[0231]

[0232] PB 0 Amino acid sequence (SEQ ID NO: 8)

[0233] VQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0234] PB 0 The encoding nucleic acid sequence (SEQ ID NO: 9)

[0235]

[0236] pAOαM recombinant expression plasmid sequence containing histidinol dehydrogenase gene (HIS4) (SEQ ID NO: 10)

[0237]

[0238] Amino acid sequence of D-BA.5 (SEQ ID NO: 11)

[0239] FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGVNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0240] The encoding nucleic acid sequence of D-BA.5 (SEQ ID NO: 12)

[0241]

[0242] Amino acid sequence of D-BQ.1.1 (SEQ ID NO: 13)

[0243] FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKFPNITNLCPFDEVFNATTFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSTVGGNYNYRYRLFRKSKLKPFERDISTEIYQAGNKPCNGVAGVNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0244] The encoding nucleic acid sequence of D-BQ.1.1 (SEQ ID NO: 14)

[0245]

[0246] Amino acid sequence of D-XBB (SEQ ID NO: 15) FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPSGNYNYLYRLFRKSKLKPFERDISTEIYQAGNKPCNGVAGSNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0247] The encoding nucleic acid sequence of D-XBB (SEQ ID NO: 16)

[0248]

[0249] Amino acid sequence of XBB-BA.5 (SEQ ID NO: 17)

[0250] FPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPSGNYNYLYRLFRKSKLKPFERDISTEIYQAGNKPCNGVAGSNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGVNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0251] The encoding nucleic acid sequence of XBB-BA.5 (SEQ ID NO: 18)

[0252]

[0253] gRNA-F (SEQ ID NO: 19)

[0254] GACCCCAAAACCAGCGAAAT

[0255] gRNA-probe (SEQ ID NO: 20)

[0256] ACTCCGCATTACGTTTGGTGGACC

[0257] gRNA-R (SEQ ID NO:21)

[0258] TCTGGTTACTGCCAGTTGAATCTG

[0259] sgRNA-F (SEQ ID NO: 22)

[0260] TGATCTCTTGTAGATCTGTTCTC

[0261] sgRNA-probe (SEQ ID NO: 23)

[0262] ACACTAGCCATCCTTACTGCGCTTCG

[0263] sgRNA-R (SEQ ID NO: 24)

[0264] ATATTGCAGCAGTACGCACACA。

Claims

1. A modified Pichia pastoris strain, It is characterized in that The modified Pichia pastoris strain is obtained by knocking out the α-1,6-mannosyltransferase gene and complementing the histidine deficiency on the basis of the Pichia pastoris GS115 strain.

2. The method for preparing the modified Pichia pastoris strain according to claim 1, It is characterized in that The preparation method comprises the following steps: (1) By genetic engineering, the α-1,6-mannosyltransferase gene in the Pichia pastoris GS115 strain was knocked out to obtain the GS115Δoch1 strain; (2) After linearizing the exogenous histidinol dehydrogenase expression plasmid, the plasmid was integrated into the GS115Δoch1 strain to obtain the modified Pichia pastoris strain.

3. A recombinant Pichia pastoris engineered bacterium, It is characterized in that The recombinant Pichia pastoris engineered bacteria is obtained by introducing the coding sequence of the SARS-CoV-2 S protein RBD antigen into the modified Pichia pastoris strain as described in claim 1.

4. The recombinant Pichia pastoris engineered bacterium according to claim 3, It is characterized in that The novel coronavirus S protein RBD antigen is a homozygous or chimeric dimer of the S protein RBD region of the SARS-CoV-2 prototype strain and / or its variant strain; Among them, the SARS-CoV-2 variants are selected from: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Omicron subtype BA.1, BA.1.1, BA.2, BA.2.12.1, BA.3, BA.4, BA.5, BQ.1.1, and XBB.

5. The recombinant Pichia pastoris engineered bacterium according to claim 4, It is characterized in that The novel coronavirus S protein RBD antigen is a dimer formed by the 329-537 amino acid fragments of the S protein RBD region of the SARS-CoV-2 prototype strain and / or its variant strain through a linker or directly connected in series, preferably a dimer formed by directly connecting in series; Preferably, the novel coronavirus S protein RBD antigen is a dimer formed by directly connecting the 329-537 amino acid fragments of the S protein RBD region of the prototype strain and the prototype strain, the prototype strain and the Beta variant, the Beta variant and the Delta variant, the Delta variant and the Omicron variant, or the Omicron variant and the Omicron variant. Further preferably, the dimer formed by directly concatenating the amino acid fragment at positions 329-537 of the S protein RBD region of the Delta variant and the Omicron variant is selected from: a dimer formed by directly concatenating the amino acid fragment at positions 329-537 of the S protein RBD region of Delta and Omicron BA.1, Delta and Omicron BA.4, Delta and Omicron BA.5, Delta and Omicron XBB, Delta and Omicron BQ.1.1; and / or, the dimer formed by directly concatenating the amino acid fragment at positions 329-537 of the S protein RBD region of the Omicron variant and the Omicron variant is selected from: a dimer formed by directly concatenating the amino acid fragment at positions 329-537 of the S protein RBD region of Omicron XBB and OmicronBQ.1.1, Omicron XBB and Omicron BA.

5.

6. The recombinant Pichia pastoris engineered bacterium according to claim 5, It is characterized in that The novel coronavirus S protein RBD antigen is selected from: (1) a dimer formed by directly connecting the amino acid fragments 329-537 of the S protein RBD region of the prototype strain and the Beta variant, whose amino acid sequence is shown in SEQ ID NO: 1, preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO: 2; (2) a dimer formed by directly connecting the amino acid fragment 329-537 of the RBD region of the S protein of Delta and Omicron BA.1 in series, wherein the amino acid sequence is as shown in SEQ ID NO:3, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO:4; (3) a dimer formed by directly connecting the amino acid fragment 329-537 of the RBD region of the S protein of Delta and Omicron BA.5 in series, wherein the amino acid sequence is as shown in SEQ ID NO: 11, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO: 12; (4) a dimer formed by directly connecting the amino acid fragment 329-537 of the S protein RBD region of Delta and Omicron BQ.1.1 in series, wherein the amino acid sequence is as shown in SEQ ID NO: 13, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO: 14; (5) a dimer formed by directly connecting the amino acid fragment 329-537 of the S protein RBD region of Delta and Omicron XBB in series, wherein the amino acid sequence is as shown in SEQ ID NO: 15, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO: 16; (6) A dimer formed by directly connecting the amino acid fragment 329-537 of the S protein RBD region of Omicron XBB and Omicron BA.5 in series, wherein the amino acid sequence is shown in SEQ ID NO: 17, and preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO:

18.

7. The method for preparing the recombinant Pichia pastoris engineered bacteria according to any one of claims 3 to 6, It is characterized in that The preparation method comprises the following steps: The coding sequence of the SARS-CoV-2 S protein RBD antigen is cloned into a Pichia pastoris expression vector to obtain a recombinant expression plasmid; after linearization, the obtained recombinant expression plasmid is transferred into the modified Pichia pastoris strain as described in claim 1 to obtain the recombinant Pichia pastoris engineered bacteria.

8. The preparation method according to claim 7, It is characterized in that The Pichia pastoris expression vector comprises the following elements: a promoter, an α-mating factor signal, a Kex2 protease recognition site, a multiple cloning site, a C-terminal His tag, and a terminator; optionally, the promoter is an AOX promoter; optionally, the terminator is an AOX terminator; Preferably, the Pichia pastoris expression vector is selected from: Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα, pPICZαA, pPICZαB, pPICZαC, pPIC9K, PichiaPink, preferably pMPICZα, whose nucleic acid sequence is shown in SEQ ID NO: 5; Optionally, the linearized recombinant expression plasmid is transferred into the modified Pichia pastoris strain as claimed in claim 1 by electroporation; Preferably, the preparation method comprises: 1) Cloning the coding sequence of the SARS-CoV-2 S protein RBD antigen into a Pichia pastoris expression vector, preferably an Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα, to obtain a recombinant expression plasmid; 2) linearizing the recombinant expression plasmid obtained in step 1) by enzyme digestion; 3) preparing competent cells of the modified Pichia pastoris strain as claimed in claim 1; 4) The linearized recombinant expression plasmid obtained in step 2) is transferred into the competent cells obtained in step 3) by electroporation to obtain the recombinant Pichia pastoris engineered bacteria.

9. Use of the recombinant Pichia pastoris engineered bacteria as described in any one of claims 3 to 6 in the preparation of a recombinant protein vaccine for the new coronavirus.

10. A method for preparing a recombinant protein vaccine of the new coronavirus, It is characterized in that The method comprises: fermenting and culturing the recombinant Pichia pastoris engineered bacteria as described in any one of claims 3 to 6, collecting the supernatant, and isolating the expressed SARS-CoV-2 S protein RBD antigen therefrom.